2seventy bio, Inc. (TSVT)
Upgrades & Downgrades
Latest TSVT news
2seventy Bio: This Spinoff In The CAR-T Space Is Attractive
8 September 2022
Shares have lost over 40% of their value since the spinoff in November. The pipeline has multiple shots on goal including in solid tumors and AML plus validating partnerships via Regeneron and BMY.
2seventy bio to Participate in Upcoming Investor Conferences
31 August 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, announced today that members of the management team will participate in the follow...
2seventy bio Prospects
23 August 2022
Abecma, a CAR-T myeloma therapy, is rapidly ramping revenue. 2seventy has $398 million in cash.
The 5 Top Profit & Protection Stocks to Buy for 2022
17 June 2022
It's important to know which quantitative factors make a stock worthwhile. These five have the attributes needed for success.